A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
NCT05649137 on ClinicalTrials.gov · last registry update 2026-04-27
Finished 28 October 2024, after enrolling 512 people. Primary outcome, as filed: Relative Change in Body Weight. semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 512
- Started
- 2023-01-04
- Primary completion
- 2024-10-28 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Relative Change in Body Weight
Conditions studied
Obesity · Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.